Developing a new drug a as a novel therapeutic strategy for aggressive leukaemia in children
Dr Michelle Henderson, Children’s Cancer Institute, Sydney
Funding period: 2019-2022.
This research project is kindly supported through the Estate of Florence Brown.
Rapidly dividing cancer cells can be dependent on a cellular biochemical called nicotinamide adenine dinucleotide (NAD) as an energy source. The Henderson laboratory discovered a new drug that blocks the production of NAD and has remarkably strong anti-leukaemia activity, even against the most aggressive subtypes of leukaemia.
This proposal aims to develop this drug as a novel therapeutic strategy for aggressive leukaemia in children, to ultimately improve their survival and minimise the side effects of treatment.